Sierra Oncology (NASDAQ:SRRA) Sees Unusually-High Trading Volume
Sierra Oncology Inc (NASDAQ:SRRA) shares saw unusually-high trading volume on Tuesday . Approximately 99,515 shares changed hands during mid-day trading, a decline of 93% from the previous session’s volume of 1,377,267 shares.The stock last traded at $0.49 and had previously closed at $0.50.
Several brokerages recently commented on SRRA. ValuEngine cut Sierra Oncology from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research raised shares of Sierra Oncology from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Saturday, November 9th.
The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.07. The company has a market cap of $25.89 million, a PE ratio of -0.67 and a beta of 1.30. The company’s fifty day moving average is $0.30 and its 200-day moving average is $0.53.
Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in shares of Sierra Oncology by 981.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 43,703 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 39,661 shares in the last quarter. Hikari Power Ltd lifted its stake in shares of Sierra Oncology by 98.4% in the 3rd quarter. Hikari Power Ltd now owns 500,138 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 248,038 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Sierra Oncology by 84.8% in the 2nd quarter. Acadian Asset Management LLC now owns 899,221 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 412,728 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Sierra Oncology by 22.0% during the 2nd quarter. Renaissance Technologies LLC now owns 2,312,634 shares of the biotechnology company’s stock valued at $1,295,000 after purchasing an additional 417,300 shares during the last quarter. Institutional investors own 48.67% of the company’s stock.
About Sierra Oncology (NASDAQ:SRRA)
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Recommended Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.